VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MDXGMiMedx Group, Inc.
$3.93$584M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksMDXGCash Flow

MiMedx Group, Inc. (MDXG) Cash Flow Statement

20Y historyFree accessUpdated daily

Cash conversion efficiency has deteriorated, as evidenced by the OCF/NI ratio plummeting to -0.17 in 2026Q1 compared to 1.64 in 2025Q4, despite maintaining a low CapEx/Revenue ratio of 1.0%.

MDXG Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06
Cash from Operations70.58M74M66.2M26.77M-17.89M-1.98M-30.26M-39.41M35.8M62.94M25.83M18.81M16.8M-285.48K-3.38M-6.66M-8.16M-8.56M-8.14M-23.67K-23.65K
Operating CF Margin %-17.68%18.97%8.33%-6.68%-0.82%-12.19%-13.17%9.97%19.6%10.54%10.04%14.21%-0.48%-12.51%-85.88%-1034.07%----
Operating CF Growth %-16.11%11.79%147.24%249.64%-802.77%93.45%23.21%-210.1%-43.13%143.69%37.33%11.93%5985.59%91.57%49.21%18.3%4.65%-5.15%-34276.9%-0.08%-
Net Income30.7M48.58M42M67.44M-19.95M-12.3M-49.28M-25.58M-29.98M64.73M11.97M29.45M6.22M-4.11M-7.66M-10.19M-11.42M-11.92M-17.37M-38.86K-16.74K
Depreciation & Amortization16.5M14.88M6.04M3.43M4.05M5.18M6.86M7.58M6.92M5.76M5.46M2.73M2.13M1.69M1.85M1.78M1.11M1.09M500.26K00
Stock-Based Compensation14.7M16.4M16.93M16.96M014.16M15.36M12.06M14.77M21.2M17.82M16.9M11.45M6.01M2.54M1.66M1.17M0000
Deferred Taxes4.18M8.71M12.47M-37.8M0001.58M25.54M-26.67M-594K-7.08M-11.45M404.9K1.8M10.51M599K-1.4M000
Other Non-Cash Items-5.99M8.42M-5.81M-4.83M6.03M10.33M12.5M-15M-53K-1.55M1.67M42K11.45M1.33M3.28M-10.19M287.45K1.41M9.11M00
Working Capital Changes3.48M-22.98M-5.43M-18.42M-8.01M-19.35M-15.69M-20.05M18.6M-523K-10.5M-23.23M-3M-5.61M-5.19M-233.23K92.96K857.16K-377.05K15.19K-6.91K
Change in Receivables9.02M-26.39M-2.55M-12.24M-5.94M-10.62M-3.1M-10.94M16.45M-479K-11.4M-27.08M-10.58M-8.44M-5.76M-1.21M-162.38K0000
Change in Inventory-2.16M-1.53M-2.36M-7.84M-1.79M-1.41M-1.26M6.88M-6.52M2.75M-2.84M-2.33M-1.25M-857.99K-2.31M-253.94K-80.63K0000
Change in Payables2.6M2.12M-1.41M783K839K-159K177K-6.17M6.58M-1.32M-3.67M3.14M1.29M1.21M-81.11K1.26M218.94K0000
Cash from Investing-12.12M-6.89M-9.58M-2.15M-2.66M-3.4M-4.55M504K-9.22M-5.4M-11.74M-678K-12.15M-3.03M-582.93K-702.51K-151.62K-356.68K593.47K00
Capital Expenditures-192K-3.12M-1.72M-2.15M-2.68M-3.22M-4.23M-2.22M-10.03M-5.4M-7.11M-6.68M-3.15M-3.03M-582.93K-486.09K-151.62K-360.49K-1.17M00
CapEx % of Revenue0.05%0.75%0.49%0.67%1%1.33%1.7%0.74%2.79%1.68%2.9%3.57%2.67%5.11%2.15%6.26%19.22%----
Acquisitions0-3.76M-7.86M024K00030K0-7.63M-6M000-466.42K001.73M00
Investments---------------------
Other Investing-11.93M0000-177K-327K2.72M808K-271K-842K5.15M-9.59M-689K-582.93K250K-151.62K6.58K36.69K00
Cash from Financing-5.12M-5.41M-34.2M-8.57M-580K-3.35M61.56M62.86M-8.93M-60.39M-8.18M-36.23M-2.15M40.63M6.61M10.14M7M2.2M3.84M17.5K30K
Debt Issued (Net)-1.13M-1M-31.72M-52K-41K-38K-25.81M70.88M-3K-29K-102K-117K-117K0-427.13K6.11M500K00010K
Equity Issued (Net)-2.56M-3.12M-2.64M-8.52M-539K-4.75M97.67M-1.47M-12.49M-72.34M-11.54M-40.28M-5.61M36.6M03.73M3.12M02.2M2.16K20K
Dividends Paid000000000000000000000
Share Repurchases-2.56M-3.12M-2.64M-9.52M-1.19M-4.75M-2.33M-1.47M-12.49M-72.34M-11.54M-40.28M-5.61M00000000
Other Financing-1.43M-1.29M159K001.44M-10.29M-6.54M3.56M11.99M3.49M4.17M3.58M4.03M7.04M295.75K3.37M2.2M63.83M0
Net Change in Cash53.34M61.7M22.42M16.05M-21.13M-8.73M26.74M23.95M17.64M-2.85M5.91M-18.1M2.5M37.32M2.64M2.77M-1.31M-6.71M-3.71M-6.17K6.35K
Free Cash Flow66.07M72.97M64.52M24.79M-19.41M-5.2M-34.49M-41.63M25.77M57.54M18.72M12.13M13.65M-3.31M-3.97M-7.15M-8.31M-8.92M-9.31M-23.67K-23.65K
FCF Margin %16.97%17.43%18.49%7.71%-7.25%-2.15%-13.89%-13.91%7.18%17.92%7.64%6.48%11.55%-5.59%-14.67%-92.14%-1053.29%----
FCF Growth %11.54%13.11%160.27%227.73%-273.21%84.92%17.15%-261.56%-55.22%207.43%54.32%-11.14%512.28%16.56%44.51%13.94%6.81%4.22%-39231.82%-0.08%-
FCF per Share0.450.490.430.17-0.17-0.05-0.32-0.390.240.500.170.110.12-0.03-0.05-0.10-0.14-0.24-1.61-0.00-0.00
FCF Conversion (FCF/Net Income)2.15x1.52x1.56x0.40x0.59x0.16x0.61x1.54x-1.19x0.97x2.16x0.64x2.70x0.07x0.44x0.65x0.71x0.72x0.47x0.61x1.41x
Interest Paid728K02.7M004.33M7.46M00000000000000
Taxes Paid4.06M03.25M00169K208K00000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowDeteriorating
Top Statement Risk

Medicare reimbursement policy shifts

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Faces Significant Headwinds

As reported in recent financial statements, the OCF/NI ratio plummeted to -0.17 in 2026Q1, a sharp reversal from the 1.64 observed in 2025Q4, indicating that the company's ability to translate accounting profits into actual cash generation remains highly volatile and sensitive to operational disruptions.

The significant divergence between net income and operating cash flow suggests that accrual-based accounting may be masking underlying cash flow volatility. Investors should monitor whether this disconnect is a temporary timing issue or a structural weakness in the company's revenue recognition and collection processes.

Free Cash Flow Volatility Persists

Based on the provided cash flow data, FCF margins contracted to 3.2% in 2026Q1 from a peak of 22.3% in 2025Q3, highlighting a deteriorating trajectory that suggests the company's core business model is struggling to maintain consistent cash generation amidst recent top-line pressures.

The erratic nature of FCF margins implies that the company's operational efficiency is highly susceptible to quarterly fluctuations in demand. This inconsistency warrants further investigation into whether the current cost structure is sufficiently flexible to withstand periods of revenue contraction.

Working Capital Swings Impact Liquidity

According to the latest quarterly filings, working capital changes contributed a substantial $15.4M inflow in 2026Q1, which stands in stark contrast to the $11.0M outflow seen in 2025Q1, suggesting that aggressive management of receivables and payables is currently driving the company's reported cash position.

The reliance on working capital adjustments to bolster cash flow may indicate that the company is pulling forward collections or delaying payments to manage liquidity. Such tactics often provide only a temporary reprieve and may not be sustainable if operational performance does not stabilize.

Capital Intensity Remains Relatively Low

As evidenced by the financial data, the company maintained a CapEx/Revenue ratio of 1.0% in 2026Q1, which remains consistent with historical trends and suggests that the business model is not overly capital-intensive despite the recent decline in overall revenue and profitability.

The low capital intensity indicates that the company does not require massive ongoing investment in physical infrastructure to support its current operations. This provides a degree of flexibility, as the company can theoretically preserve cash by scaling back discretionary spending without immediately impairing its core production capabilities.

MDXG — Frequently Asked Questions

Quick answers to the most common questions about buying MDXG stock.

How much cash does MiMedx Group, Inc. (MDXG) generate from operations?

MiMedx Group, Inc. (MDXG) generated $74.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is MiMedx Group, Inc.'s free cash flow?

MiMedx Group, Inc. (MDXG) generated $73.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is MiMedx Group, Inc.'s capital expenditure (CapEx)?

MiMedx Group, Inc. (MDXG) spent $3.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does MiMedx Group, Inc. distribute cash to shareholders?

In 2025, MiMedx Group, Inc. (MDXG) spent $3.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.